MAPT and Alzheimer disease: Conventional AD drugs targeting the underlying pathology, such as amyloid plaque accumulation and tau protein abnormalities, encounter a challenge when they cross the BBB, which is responsible for regulating the passage of substances from the bloodstream into the brain [17].